MW

Michael S. Weiss

Chairman at Checkpoint Therapeutics

Mr. Weiss has served as our Chairman of Board of Directors since March 2015, as well as our Interim Chief Executive Officer and President from August 2015 until October 2015 and Executive Chairman from March 2015 to December 2016. Mr. Weiss is also director and Executive Vice Chairman, Strategic Development, of Fortress Biotech and Chairman of the Board of Directors and Executive Chairman of Mustang Bio, Inc. Additionally, he holds the role of Executive Chairman, President and Chief Executive Officer of TG Therapeutics, a company he founded in 2011, and Co-Portfolio Manager and Partner of Opus Point Partners, LLC, which he co-founded in 2009. From 2002 to 2009, Mr. Weiss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, where he helped the company acquire and develop its lead drug, Auryxia, and executed a strategic alliance for Auryxia with Japan Tobacco and Torii Pharmaceutical Co. Mr. Weiss began his professional career as a lawyer with Cravath, Swaine & Moore LLP. He earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany.


Timeline

  • Chairman

    Current role